Are Atrial Fibrillation Patients Receiving Warfarin in Accordance with Stroke Risk?

被引:125
|
作者
Zimetbaum, Peter J. [1 ]
Thosani, Amit
Yu, Hsing-Ting [2 ]
Xiong, Yan [2 ]
Lin, Jay [3 ]
Kothawala, Prajesh [2 ]
Emons, Matthew [2 ]
机构
[1] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA
[2] Cerner LifeSci, Beverly Hills, CA USA
[3] Sanofi Aventis, Bridgewater, NJ USA
来源
AMERICAN JOURNAL OF MEDICINE | 2010年 / 123卷 / 05期
关键词
Anticoagulation; Atrial fibrillation; Atrial flutter; Stroke risk; Warfarin; RHYTHM-CONTROL; ORAL ANTICOAGULATION; MANAGEMENT; THERAPY; PREVENTION; GUIDELINES; IMPACT;
D O I
10.1016/j.amjmed.2009.11.015
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Clinical guidelines for the management of atrial fibrillation and atrial flutter provide recommendations for anticoagulation based on patients' overall risk of stroke. To determine the real-world compliance of physicians with these recommendations, we conducted a retrospective cohort study examining the utilization of warfarin in atrial fibrillation/flutter patients by stroke risk level. METHODS: Patients with a qualifying atrial fibrillation/flutter diagnosis during >= 18 months' continuous enrollment between January 2003 and September 2007, and with >= 6 months' eligibility after the first atrial fibrillation/flutter diagnosis, were identified from the US Market Scan database (Thomson Reuters, New York, NY). Warfarin use within 30 days of the first diagnosis was assessed according to stroke risk, estimated using the Congestive heart failure, Hypertension, Age >75 years, Diabetes, Stroke (CHADS(2)) score. RESULTS: Of 171,393 patients included in the analysis, 20.0% had a CHADS(2) score of 0 (low risk), 61.6% a score of 1-2 (moderate risk), and 18.4% a score of 3-6 (high risk). Warfarin, recommended for high stroke-risk patients, was given to only 42.1% of those with a CHADS(2) score of 3-6. A similar percentage of patients with moderate (43.5%) or low stroke risk (40.1%) received warfarin. Only 29.6% of high-risk, 33.3% of moderate-risk, and 34.1% of low-risk patients who were started on warfarin received. uninterrupted therapy for 6 months following their initial prescription. CONCLUSIONS: These data suggest that guideline recommendations that anticoagulation should be provided in accordance with stroke risk in atrial fibrillation patients are not routinely followed in clinical practice. The causes and clinical implications of under-utilization of anticoagulation in atrial fibrillation patients with high stroke risk warrant further study. (c) 2010 Elsevier Inc. All rights reserved. The American Journal of Medicine (2010) 123, 446-453
引用
收藏
页码:446 / 453
页数:8
相关论文
共 50 条
  • [41] ARE PATIENTS WITH STROKE AND ATRIAL FIBRILLATION RECEIVING APPROPRIATE ANTICOAGULATION?
    Phyu, Cho Thae
    Taylor, Caroline
    Khan, Zainab
    Cowell, Richard
    HEART, 2014, 100 : A7 - A7
  • [42] Underutilization of warfarin for stroke prophylaxis in patients with atrial fibrillation or atrial flutter in Korea
    Lee, Iyn-Hyang
    Kim, Hyunah
    Je, Nam Kyung
    JOURNAL OF CARDIOLOGY, 2015, 66 (5-6) : 475 - 481
  • [43] Prevalence of atrial fibrillation and warfarin use in older patients receiving hemodialysis
    Winkelmayer, Wolfgang C.
    Liu, Jun
    Patrick, Amanda R.
    Setoguchi, Soko
    Choudhry, Niteesh K.
    JOURNAL OF NEPHROLOGY, 2012, 25 (03) : 341 - 353
  • [44] Use of warfarin and performance of stroke risk stratification models in atrial fibrillation
    Palacio, A.
    Parris, D.
    Chirinos, J.
    Lopez-Sanabria, B.
    Chen, G.
    Florez, H.
    Tamariz, L.
    EUROPEAN HEART JOURNAL, 2006, 27 : 836 - 836
  • [45] Risk of Stroke and Bleeding in Atrial Fibrillation Treated with Apixaban Compared with Warfarin
    Bradley, Marie
    Welch, Emily C.
    Eworuke, Efe
    Graham, David J.
    Zhang, Rongmei
    Huang, Ting-Ying
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2020, 35 (12) : 3597 - 3604
  • [46] Risk of Stroke and Bleeding in Atrial Fibrillation Treated with Apixaban Compared with Warfarin
    Marie Bradley
    Emily C. Welch
    Efe Eworuke
    David J. Graham
    Rongmei Zhang
    Ting-Ying Huang
    Journal of General Internal Medicine, 2020, 35 : 3597 - 3604
  • [47] Use of warfarin and performance of stroke risk stratification models in atrial fibrillation
    Tamariz, Leonardo
    Parris, Donald
    Chirinos, Julio
    Lopez-Sanabria, Bernardo
    Chen, Gordon
    Palacio, Ana
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (09) : 5A - 5A
  • [48] Risk of stroke and bleeding in atrial fibrillation treated with apixaban compared to warfarin
    Bradley, Marie C.
    Welch, Emily C.
    Eworuke, Efe
    Graham, David
    Zhang, Rongmei
    Huang, Ting-Ying
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 6 - 7
  • [49] Re: Quality of warfarin therapy and risk of stroke, bleeding, and mortality among patients with atrial fibrillation
    van Miert, Jasper H. A.
    Meijer, Karina
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 (02) : 243 - 243
  • [50] Warfarin Use and Risk of Stroke in Patients With Atrial Fibrillation Undergoing Hemodialysis A Meta-Analysis
    Lee, Meng
    Saver, Jeffrey L.
    Hong, Keun-Sik
    Wu, Yi-Ling
    Huang, Wen-Hong
    Rao, Neal M.
    Ovbiagele, Bruce
    MEDICINE, 2016, 95 (06)